文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

质子放疗对儿童青少年霍奇金病的优势

Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease.
PubMed 文献 · Radiat Oncol · 2019-09-02

质子放疗显著降低多数危及器官剂量,且适形性和均匀性略优,基于文献数据可显著降低继发乳腺癌、肺癌及缺血性心脏事件风险。

要点

  • 质子计划较光子计划显著降低心脏、肺、甲状腺和乳腺等危及器官剂量。
  • 质子计划靶区覆盖与光子计划相当,适形性和均匀性略优。
  • 基于文献数据,质子放疗可显著降低继发乳腺癌、肺癌和缺血性心脏病风险。

核心结论

  • 纵隔霍奇金淋巴瘤质子放疗对几乎所有危及器官显著降低剂量,适合减少儿童青少年长期副作用。

研究设计与样本

  • 靶区由F18-FDG PET阳性区域定义,采用改良受累淋巴结照射方法。
  • 使用ICRU 83建议的适形指数和均匀性指数评估计划,危及器官平均剂量用非参数Kruskal-Wallis检验及两两比较。

主要发现

  • 质子计划较三种光子计划显著降低危及器官剂量,中位剂量和平均剂量均降低。
  • 质子计划靶区覆盖与光子计划相当,适形性和均匀性略优。
  • 基于文献数据,质子放疗可显著降低继发乳腺癌、继发肺癌和缺血性心脏事件风险。

关键数值与推荐

  • 处方剂量为28.8 Gy(EURO-NET-PHL-C2)。
  • 靶区定义为F18-FDG PET阳性区域,采用改良受累淋巴结照射方法。

临床怎么用

  • 对儿童青少年纵隔霍奇金淋巴瘤,质子放疗可在保证靶区覆盖的同时降低危及器官剂量和长期毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Radiotherapy is frequently used in the therapy of lymphoma. Since lymphoma, for example Hodgkin's disease, frequently affect rather young patients, the induction of secondary cancer or other long-term adverse effects after irradiation are important issues to deal with. Especially for mediastinal manifestations numerous organs and substructures at risk play a role. The heart, its coronary vessels and cardiac valves, the lungs, the thyroid and, for female patients, the breast tissue are only the most important organs at risk. In this study we investigated if proton-radiotherapy might reduce the dose delivered to the organs at risk and thus minimize the therapy-associated toxicity. METHODS: In this work we compared the dose delivered to the heart, its coronary vessels and valves, the lungs, the thyroid gland and the breast tissue by different volumetric photon plans and a proton plan, all calculated for a dose of 28.8 Gy (EURO-NET-PHL-C2). Target Volumes have been defined by F18-FDG PET-positive areas, following a modified involved node approach. Data from ten young female patients with mediastinal lymphoma have been evaluated. Three different modern volumetric IMRT (VMAT) photon plans have been benchmarked against each other and against proton-irradiation concepts. For plan-evaluation conformity- and homogeneity-indices have been calculated as suggested in ICRU 83. The target volume coverage as well as the dose to important organs at risk as the heart with its substructures, the lungs, the breast tissue, the thyroid and the spinal cord were calculated and compared. For statistical evaluation mean doses to organs at risk were evaluated by non- parametric Kruskal-Wallis calculations with pairwise comparisons. RESULTS: Proton-plans and three different volumetric photon-plans have been calculated. Proton irradiation results in significant lower doses delivered to organ at risk. The median doses and the mean doses could be decreased while PTV coverage is comparable. As well conformity as homogeneity are slightly better for proton plans. For several organs a risk reduction for secondary malignancies has been calculated using literature data as reference. According to the used data derived from literature especially the secondary breast cancer risk, the secondary lung cancer risk and the risk for ischemic cardiac insults can be reduced significantly by using protons for radiotherapy of mediastinal lymphomas. CONCLUSION: Irradiation with protons for mediastinal Hodgkin-lymphoma results in significant lower doses for almost all organs at risk and is suitable to reduce long term side effects for pediatric and adolescent patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lautenschlaeger S, Iancu G, Flatten V, et al. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease. Radiat Oncol. 2019. PMID: 31477141. doi:10.1186/s13014-019-1360-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。